J-NE can have a therapeutic effect on CGN by affecting the expression of CCL7, LCN2, CCL2, and CXCL1, thereby altering the inflammatory response and controlling the IL-17 signaling pathway, and is a promising drug candidate for the treatment of CGN. The gene discussed is LCN2; the disease is childhood gender nonconformity.